Dicerna Pharmaceuticals (DRNA) Shares Down 0.7%

Dicerna Pharmaceuticals (NASDAQ:DRNA)’s share price fell 0.7% on Wednesday . The stock traded as low as $12.98 and last traded at $13.41. 20,484 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 539,225 shares. The stock had previously closed at $13.32.

Several brokerages recently weighed in on DRNA. HC Wainwright restated a “hold” rating and issued a $14.00 price objective on shares of Dicerna Pharmaceuticals in a report on Tuesday. BidaskClub upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 4th. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 1st. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, April 24th. Finally, ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $12.88.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.57. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. The firm had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. sell-side analysts expect that Dicerna Pharmaceuticals will post -1.64 earnings per share for the current year.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total value of $150,000.00. Following the completion of the sale, the insider now owns 19,800 shares of the company’s stock, valued at $297,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James B. Weissman sold 8,965 shares of the company’s stock in a transaction that occurred on Friday, April 20th. The shares were sold at an average price of $13.00, for a total transaction of $116,545.00. Following the completion of the sale, the insider now directly owns 9,800 shares of the company’s stock, valued at approximately $127,400. The disclosure for this sale can be found here. Insiders sold 20,000 shares of company stock valued at $280,000 in the last ninety days. Insiders own 19.85% of the company’s stock.

A number of large investors have recently modified their holdings of the business. Millennium Management LLC increased its position in shares of Dicerna Pharmaceuticals by 509.1% during the first quarter. Millennium Management LLC now owns 407,530 shares of the biopharmaceutical company’s stock worth $3,896,000 after acquiring an additional 340,623 shares in the last quarter. Caxton Corp bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $125,000. Verition Fund Management LLC bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $141,000. Cubist Systematic Strategies LLC bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $102,000. Finally, Jane Street Group LLC bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $136,000. 74.45% of the stock is owned by hedge funds and other institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply